Skip to content
Taxonomy
CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E
The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28 Read More
Understanding Charcot-Marie-Tooth Disease in Children
This CMT awareness month, the CMTA’s Chief Research Officer, Katherine Read More
Muscular Dystrophy Association and Charcot-Marie-Tooth Association Announce Collaborative Non-Viral Gene Therapy Research Grant
New York, NY – September 12, 2023 — The Muscular Read More
CMTA Hails Novartis Acquisition of DTx Pharma And Its CMT1A Therapeutic Program
The Charcot-Marie-Tooth Association July 17 hailed the news that global Read More
Development of Treatments for CMT2D
Professor Robert Burgess and his team at The Jackson Laboratory Read More
CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients
The Charcot-Marie-Tooth Association (CMTA) announced the results of a review Read More
A New Therapeutic Strategy for CMT2D
Scientists at the UCL Queen Square Institute of Neurology in Read More
Development of Advanced Research Diagnostic Capabilities for the CMT Community
CMT is a genetic disease caused by distinct changes in Read More
Studying Neurodegeneration in CMT1X Mouse Model
In people with CMT1X cell-to-cell communication within the peripheral nervous Read More
Establishing gene therapy strategies for CMT2E
CMT2E is caused by dominant or recessive mutations in the Read More
